Jeffrey Kordower to Genetic Therapy
This is a "connection" page, showing publications Jeffrey Kordower has written about Genetic Therapy.
Connection Strength
9.099
-
Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. Brain. 2020 03 01; 143(3):960-975.
Score: 0.645
-
Parkinson's disease gene therapy: Will focused ultrasound and nanovectors be the next frontier? Mov Disord. 2019 09; 34(9):1279-1282.
Score: 0.604
-
Disease Modification Through Trophic Factor Delivery. Methods Mol Biol. 2018; 1780:525-547.
Score: 0.555
-
Therapeutic approaches to target alpha-synuclein pathology. Exp Neurol. 2017 12; 298(Pt B):225-235.
Score: 0.546
-
Gene therapy for Parkinson's disease: still a hot topic? Neuropsychopharmacology. 2015 Jan; 40(1):255-6.
Score: 0.451
-
Trophic factor gene therapy for Parkinson's disease. Mov Disord. 2013 Jan; 28(1):96-109.
Score: 0.392
-
Introduction: gene therapy has gone from a pipe dream to clinical reality. Neurobiol Dis. 2012 Nov; 48(2):151-2.
Score: 0.380
-
Gene therapy for Huntington's disease. Neurobiol Dis. 2012 Nov; 48(2):243-54.
Score: 0.366
-
GDNF family ligands: a potential future for Parkinson's disease therapy. CNS Neurol Disord Drug Targets. 2011 Sep 01; 10(6):703-11.
Score: 0.358
-
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord. 2011 Jan; 26(1):27-36.
Score: 0.339
-
Gene therapy for Parkinson's disease. Mov Disord. 2010; 25 Suppl 1:S161-73.
Score: 0.319
-
Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther. 2010 Mar; 18(3):579-87.
Score: 0.313
-
Trophic factors therapy in Parkinson's disease. Prog Brain Res. 2009; 175:201-16.
Score: 0.297
-
Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiol Dis. 2009 Apr; 34(1):40-50.
Score: 0.297
-
Future of cell and gene therapies for Parkinson's disease. Ann Neurol. 2008 Dec; 64 Suppl 2:S122-38.
Score: 0.296
-
Regulatable promoters and gene therapy for Parkinson's disease: is the only thing to fear, fear itself? Exp Neurol. 2008 Jan; 209(1):34-40.
Score: 0.271
-
Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiol Dis. 2007 May; 26(2):375-84.
Score: 0.260
-
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol. 2006 Dec; 60(6):706-15.
Score: 0.257
-
Gene transfer of trophic factors and stem cell grafting as treatments for Parkinson's disease. Neurology. 2006 May 23; 66(10 Suppl 4):S89-103.
Score: 0.248
-
Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10?Years CERE120 Delivery. Mov Disord. 2023 09; 38(9):1728-1736.
Score: 0.204
-
Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol. 2003 Jun; 181(2):213-23.
Score: 0.202
-
In vivo gene delivery of glial cell line--derived neurotrophic factor for Parkinson's disease. Ann Neurol. 2003; 53 Suppl 3:S120-32; discussion S132-4.
Score: 0.196
-
Neuroprotection for Parkinson's disease using viral vector-mediated delivery of GDNF. Prog Brain Res. 2002; 138:421-32.
Score: 0.183
-
AAV2-Neurturin for Parkinson's Disease: What Lessons Have We Learned? Methods Mol Biol. 2016; 1382:485-90.
Score: 0.121
-
Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy. Brain. 2015 Dec; 138(Pt 12):3555-66.
Score: 0.119
-
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
Score: 0.116
-
A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014 Sep; 10(5):571-81.
Score: 0.105
-
Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis. 2011 Oct; 44(1):38-52.
Score: 0.088
-
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Dec; 9(12):1164-1172.
Score: 0.084
-
Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res. 2010; 184:237-64.
Score: 0.080
-
AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis. 2007 Jul; 27(1):67-76.
Score: 0.066
-
Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point. Parkinsonism Relat Disord. 2007; 13 Suppl 3:S469-77.
Score: 0.065
-
Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9345-50.
Score: 0.062
-
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005 May; 11(5):551-5.
Score: 0.058
-
Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci. 2002 Jun 15; 22(12):4942-54.
Score: 0.047
-
Anti-a-synuclein ASO delivered to monoamine neurons prevents a-synuclein accumulation in a Parkinson's disease-like mouse model and in monkeys. EBioMedicine. 2020 Sep; 59:102944.
Score: 0.042
-
GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. J Parkinsons Dis. 2020; 10(3):875-891.
Score: 0.040
-
Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with a-synucleinopathies. Neurobiol Dis. 2015 Jun; 78:162-71.
Score: 0.029